Concomitant use of drugs that are strong inducers of the cytochrome P450 CYP3A is contraindicated due to decreased therapeutic effect and resistance of drug. Some common drugs that are strong CYP3A inducers include dexamethasone, phenytoin, carbamazepine, rifampin and St. John's Wort.<unk>  is a CYP3A and p-glycoprotein substrate, therefore, drugs that are strong inducers or inhibitors of these enzyme will interfere with<unk>  levels in the body. Dose modifications are made with concomitant use of<unk>  and drugs that affect CYP3A or p-gp. When taking<unk>  with non-nucleoside reverse transcriptase inhibitors, the dose of<unk>  is increased to overcome CYP3A induction. The dose for<unk>  should be lowered when taking with antifungals, such as ketoconazole. Currently, there are no required dosage adjustments with concurrent use of<unk>  and immunosuppressants, narcotic analgesics, antidepressants, sedatives, and cardiovascular agents. Concurrent use with amiodarone, sofosbuvir and<unk>  has may result in an increased risk for serious slowing of the heart rate.
Daclatasvir
Balapiravir
Odalasvir
Telaprevir
Remdesivir
Favipiravir
Ledipasvir
Entecavir